drugset / Trial / NCT04448184
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Phase 3
Recruiting
662 enrolled
Ottawa Hospital Research Institute
Alberta Cancer Foundation · collab
RandomizedParallel-groupOpen-labelOther
Summary
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Timeline
- Start
- 2022-02-16
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tranexamic Acid | Small molecule | 1 g | Oral |